Clinical trials
Metastatic Cervical Cancer clinical trials
Below are recruiting metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 349 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06771193Recruiting
Study of cervical cancer treatment patterns in Italy
This study looks at the types of treatments and disease characteristics in people with cervical cancer that is locally advanced (cannot be removed by surgery) or has come back or spread. It may help doctors understand how different treatments are used in Italy.
Bologna, BolognaAges 18 years+ - NCT06755515Enrolling by invitationPhase 2/Phase 3
Rulonilimab + Chemo for Advanced Cervical Cancer
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
Linyi, ShandongAges 18 years+ - NCT06698458Recruiting
DaRT radiation plus chemo for advanced pancreatic cancer
This trial tests a new type of radiation called DaRT (Alpha DaRT) combined with standard chemotherapy for people with pancreatic cancer that is locally advanced or has spread. The goal is to see if adding this radiation treatment can help shrink tumors or slow the cancer's growth.
Gilbert, ArizonaAges 18–120 - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT03958240Recruiting
Study how cancers trigger the immune system
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
ToulouseAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT05990803RecruitingPhase 2
Testing new drugs for advanced cervical and gynecologic cancers
This trial tests a new drug called BL-B01D1, alone or combined with another drug (SI-B003), for people with cervical or other gynecologic cancers that have spread or come back after standard treatments. The goal is to see if this treatment can help when other options have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06266338RecruitingPhase 2
Pembrolizumab and lenvatinib for recurrent or metastatic cervical cancer
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Dallas, TexasAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06245356RecruitingPhase 2
A safety trial of trifluridine/tipiracil for DPD-deficient patients
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
AmiensAges 18 years+ - NCT05296564RecruitingPhase 1/Phase 2
TCR cell therapy for NY-ESO-1 positive metastatic cancers
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
JerusalemAges 18–70 - NCT06157151RecruitingPhase 2
New drug plus pembrolizumab for advanced cervical cancer
This trial tests a new experimental drug, PRGN-2009, combined with the immunotherapy pembrolizumab (Keytruda) for people with HPV-related cervical cancer that has come back or spread. It is for those who have already tried pembrolizumab and are looking for another option.
Little Rock, ArkansasAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06079671RecruitingPhase 3
Volrustomig for high-risk locally advanced cervical cancer
This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.
Birmingham, AlabamaAges 15 years+ - NCT05914974Recruiting
Tracking inflammation changes during immunotherapy in gynecologic cancer
This trial looks at how a blood inflammation marker (CRP) changes when people with metastatic gynecologic cancers receive immunotherapy, sometimes together with palliative chemotherapy. The goal is to see patterns that may help doctors better understand and manage treatment responses to immunotherapy.
TübingenAges 18 years+ - NCT05798819RecruitingPhase 3
PD-L1 cervical cancer trial with chemotherapy and possible bevacizumab
This Phase 3 study tests GLS-010 added to standard platinum chemotherapy, with or without bevacizumab, as a first treatment for cervical cancer that has persisted, come back, or spread. If you have PD-L1–positive tumors, the goal is to improve how long people can control the cancer compared with standard chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05686226RecruitingPhase 2
Trial tests immune cells targeting HPV-16 cancers
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Bethesda, MarylandAges 18 years+ - NCT05475171RecruitingPhase 2
Combination treatment for advanced cervical cancer
This study tests a new combination of immunotherapy drugs for cervical cancer that has spread or returned. It aims to see if the treatment can shrink tumors and improve outcomes for people whose cancer is not curable with standard treatments.
Houston, TexasAges 18 years+ - NCT05483491RecruitingPhase 1
TCR cell therapy for select metastatic cancers
This Phase 1 trial tests a personalized immune-cell treatment (TCR-T cells) for certain metastatic cancers. It targets cancers that carry a specific marker and requires patients to have a specific immune-system match, aiming to improve cancer control when standard options were already tried.
New Brunswick, New JerseyAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT05283330RecruitingPhase 1
Tested 212Pb imaging drug for certain advanced GRPR tumors
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Chicago, IllinoisAges 18 years+ - NCT04965766RecruitingPhase 2
Study drug for HER2-negative, advanced breast cancer after prior treatment
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
DijonAges 18 years+ - NCT05232409RecruitingPhase 1
Zeaxanthin in metastatic cancer, alone or with pembrolizumab
This Phase 1 study tests whether zeaxanthin is safe and what dose to use in people with metastatic cancer. It also studies zeaxanthin together with pembrolizumab (an immunotherapy) to see if the combination is tolerable after cancer has progressed despite PD-1/PD-L1 treatment.
Paramus, New JerseyAges 18–99 - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+
Hear when a new Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cervical cancer?
- Yes. Clin2 currently lists 349 recruiting metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.